<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="106069">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02140762</url>
  </required_header>
  <id_info>
    <org_study_id>V102_16</org_study_id>
    <nct_id>NCT02140762</nct_id>
  </id_info>
  <brief_title>Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents</brief_title>
  <official_title>A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adolescents in the U.S.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effectiveness of 2 doses of MenABCWY vaccine in adolescents compared to a
      single dose of MenACWY vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Percentages of  N. meningitidis serogroup B invasive disease strains killed at 1:4 and 1:8 dilutions, for each subject</measure>
    <time_frame>1 Month after 2-Dose vaccination Series</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of N. meningitidis serogroup B invasive disease strains killed at 1:4 and 1:8 dilutions, for each subject</measure>
    <time_frame>4 Months after 2-dose Vaccination Series</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>percentages of subjects with hSBA ≥ 1:4 and hSBA titer ≥ 1:8 against four N. meningitidis serogroup B test strains</measure>
    <time_frame>1 Month after 2-Dose vaccination Series</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>percentages of subjects with hSBA ≥ 1:4 and hSBA titer ≥ 1:8 against four N. meningitidis serogroup B test strains</measure>
    <time_frame>4 Months after 2-Dose Vaccination Series</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>percentages of subjects with hSBA titers against serogroup B test strains ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128</measure>
    <time_frame>one month after 2-dose vaccination series</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>percentages of subjects with hSBA titers against serogroup B test strains ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128</measure>
    <time_frame>four Months after 2-dose vaccination series</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events and other indicators of reactogenicity</measure>
    <time_frame>Day 1 to 6 months.</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentages of subjects with two-, three- and four-fold rise in hSBA titer against serogroup B test strains</measure>
    <time_frame>one month after 2-dose vaccination series</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentages of subjects with two-, three- and four-fold rise in hSBA titer against serogroup B test strains</measure>
    <time_frame>Four months after 2-dose vaccination series</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA Geometric Mean Titers against serogroup B test strains</measure>
    <time_frame>one month after 2-dose vaccination series</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA Geometric Mean Titers against serogroup B test strains</measure>
    <time_frame>Four months after 2-dose vaccination series</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentages of subjects with hSBA titers ≥ LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against serogroups A, C, W, Y</measure>
    <time_frame>one month after 2-dose vaccination series</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentages of subjects with hSBA titers ≥ LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against serogroups A, C, W, Y</measure>
    <time_frame>Four Months after 2-Dose vaccination series</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentages of subjects with two-, three- and four-fold rise in hSBA titer against serogroups A, C, W and Y</measure>
    <time_frame>One month after 2-dose vaccination series</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentages of subjects with two-, three- and four-fold rise in hSBA titer against serogroups A, C, W and Y</measure>
    <time_frame>Four months after 2-Dose vaccination Series</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA Geometric Mean Titers to serogroups A, C, W, and Y</measure>
    <time_frame>One month after 2-dose vaccination series</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA Geometric Mean Titers to serogroups A, C, W, and Y</measure>
    <time_frame>Four Months after 2-dose vaccination series</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Meningococcal Disease</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MenABCWY</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MenACWY</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenABCWY</intervention_name>
    <description>Effectiveness</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY</intervention_name>
    <description>Effectiveness</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adolescents from 10-18 years of age, generally in good health, and available for all
             study visits, who/whose legally acceptable representative has given written informed
             consent at the time of enrollment.

          -  Female subjects of childbearing potential must have a negative urine pregnancy test.

        Exclusion Criteria:

          -  Serious, acute, or chronic illnesses. Previous or suspected disease caused by N.
             meningitidis. Previous immunization with any meningococcal vaccine.

          -  Exposure to individuals with clinically proven meningococcal disease or clinical
             bacterial meningitis without further microbiologic characterization.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Drug Information Services</last_name>
    <phone>+1 800 244 7668</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Accelovance, Inc</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Children's Clinic of Jonesboro, P.A.</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Accelovance, Inc</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates LLC</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bluegrass Clinical Research, Inc.</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Senders Pediatrics</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Adu-Bobie J, Capecchi B, Serruto D, Rappuoli R, Pizza M. Two years into reverse vaccinology. Vaccine. 2003 Jan 30;21(7-8):605-10. PubMed</citation>
    <PMID>12531326</PMID>
  </reference>
  <reference>
    <citation>Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther. 2011 Jul;11(7):969-85. doi: 10.1517/14712598.2011.585965. Epub 2011 May 26. Review. PubMed</citation>
    <PMID>21615224</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>May 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningitis ABCWY</keyword>
  <keyword>adolescents</keyword>
  <keyword>accination</keyword>
  <keyword>meningococcal disease</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
